News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GPC Biotech, Inc.: New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at American Association for Cancer Research


4/21/2009 10:00:33 AM

MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC) today reported that pre-clinical data on RGB-286638, the Company’s multi-targeted protein kinase inhibitor, are being presented at the American Association for Cancer Research (AACR) 100th Annual Meeting in Denver, Colorado. Researchers from the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center (MGH), Boston, Massachusetts gave an oral presentation entitled, “A Novel Multi-Targeted Small Molecule Inhibitor RGB-286638 Triggers Apoptosis and Necrosis in Multiple Myeloma via Dual Cell Death Pathways.” The data show that RGB-286638 demonstrates in vivo activity in several pre-clinical models of multiple myeloma. The compound also induces cell death in multiple myeloma cells independent from the p53 status; p53 is a gene involved in the control of cell proliferation.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES